Business Context and Reporting Period
This Form 8-K was filed by Atea Pharmaceuticals, Inc. on July 19, 2021. The report discloses the entry into a material definitive agreement regarding the company's principal executive offices.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a new lease obligation:
- Lease Term: January 1, 2022, to December 31, 2026.
- Initial Base Rent: $65,790 per month.
- Rent Escalation: 2% annual increase starting on the first anniversary of the commencement date.
- Additional Costs: Company is responsible for operating expenses, taxes, and utilities.
- Leasehold Improvement Allowance: $877,200 provided by the landlord (DataRobot, Inc.).
Material Changes
The company is relocating its principal executive offices from 125 Summer Street, Boston (lease expiring July 2022), to 17,544 square feet on the 21st floor of 225 Franklin Street, Boston. This move is contingent upon the continued existence of the master lease held by DataRobot, Inc.
Outlook, Risks, and Contingencies
Contingency: The sublease is explicitly conditioned on DataRobot, Inc. maintaining its lease with the building owner (225 Franklin Owner (DE) LLC). If the master lease terminates, the sublease may be affected.
Management Commentary: The filing notes that the new premises are expected to serve as the company's principal executive offices once occupied.
Key Facts for Investor Verification
- Verify the stability of the master lease held by DataRobot, Inc., as the Atea sublease is dependent on it.
- Confirm the total projected occupancy costs including the 2% annual rent escalations and estimated operating expenses.
- Monitor the timeline for the lease commencement (January 1, 2022) and the expiration of the current lease (July 2022) to ensure a seamless transition.
- Review the specific terms of the $877,200 leasehold improvement allowance to understand any usage restrictions or clawback provisions.